Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7C3JA
|
|||
| Drug Name |
UCART-22
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3; ICD-10: C91, C91.9] | Phase 1 | [1] | |
| Company |
Cellectis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell receptor CD22 (CD22) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | B Cell Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04150497) Phase I Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cellectis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.